Evaluation of the Serum Soluble Fractalkine as a Biomarker of Pulmonary Fibrosis in Systemic Sclerosis (SCLEROLUNG)
Primary Purpose
Systemic Scleroderma
Status
Unknown status
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
blood samples
Sponsored by
About this trial
This is an interventional basic science trial for Systemic Scleroderma
Eligibility Criteria
Inclusion Criteria:
- Patients over the age of 18 with SSc with or without ILD with a medical follow up in AP-HM
- Patients, followed at AP-HM, with IPF
Exclusion Criteria:
- Impossibility of taking blood
- Known diagnosis of respiratory disorders other than SSc-associated ILD and IPF
- An infection in progress
- An evolutive cancer
- Chemotherapy or radiation therapy in progress
- Minors
- Pregnant or lactating women
- Majors under guardianship
- People staying in a health or social facility
- People in emergency
- Non-beneficiaries of a social security scheme
- Persons deprived of their liberty
Sites / Locations
- Assistance Publique Hopitaux de MarseilleRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Active Comparator
Arm Label
SSc without ILD
SSc with ILD
patients with idiopathic pulmonary fibrosis
Arm Description
Outcomes
Primary Outcome Measures
fractalkine levels
Secondary Outcome Measures
Full Information
NCT ID
NCT03508375
First Posted
April 16, 2018
Last Updated
June 17, 2019
Sponsor
Assistance Publique Hopitaux De Marseille
1. Study Identification
Unique Protocol Identification Number
NCT03508375
Brief Title
Evaluation of the Serum Soluble Fractalkine as a Biomarker of Pulmonary Fibrosis in Systemic Sclerosis
Acronym
SCLEROLUNG
Official Title
Evaluation of the Serum Soluble Fractalkine as a Biomarker of Pulmonary Fibrosis in Systemic Sclerosis
Study Type
Interventional
2. Study Status
Record Verification Date
June 2019
Overall Recruitment Status
Unknown status
Study Start Date
May 15, 2018 (Actual)
Primary Completion Date
May 2021 (Anticipated)
Study Completion Date
November 2021 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique Hopitaux De Marseille
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Systemic Scleroderma (SCS) is an autoimmune disease characterized by vascular involvement, a dysimmune condition, cutaneous and visceral fibrosis. Interstitial lung disease (ILD) affects 75% of SSc patients and is the leading cause of death in SSc. No diagnostic or prognostic biomarkers of SSc-associated ILD have been validated to date. The search for such a serum biomarker is essential to assess the severity of these patients and to help the therapeutic management.
We have shown that soluble fractalkine is elevated in SSc patients, especially in SSc patients with ILD. The fractalkine is both an endothelial adhesion molecule and a chemokine that binds to the CX3CR1 receptor expressed by immune populations. It would thus reflect the vasculopathy and inflammation that lead to the fibrosing pulmonary involvement of this disease.
Objectives and means: We aim to perform a low-risk interventional biomedical research which main objective is the quantitative evaluation of soluble fractalkine in SSc patients with ILD in comparison with SSc patients without ILD. This epidemiological, explanatory, analytical, single-center study will comprise three groups: 1 / SSc without ILD (control group in the context of SSc), 2/ SSc with ILD and 3/ patients with idiopathic pulmonary fibrosis (IPF) (control group of the ILD). Secondary objectives are evaluation of: 1 / fractalkine levels in the IPF, 2 / correlations between fractalkine levels and severity of ILD and of SSc disease over time, 3 / correlations between fractalkine and 2 other biomarkers: KL-6 (marker of pulmonary fibrosis) and soluble CD146 (sCD146, marker of vasculopathy), 4 / predictive values of the decline in lung function of these 3 markers.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Systemic Scleroderma
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
75 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
SSc without ILD
Arm Type
Experimental
Arm Title
SSc with ILD
Arm Type
Experimental
Arm Title
patients with idiopathic pulmonary fibrosis
Arm Type
Active Comparator
Intervention Type
Biological
Intervention Name(s)
blood samples
Intervention Description
blood samples
Primary Outcome Measure Information:
Title
fractalkine levels
Time Frame
24 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients over the age of 18 with SSc with or without ILD with a medical follow up in AP-HM
Patients, followed at AP-HM, with IPF
Exclusion Criteria:
Impossibility of taking blood
Known diagnosis of respiratory disorders other than SSc-associated ILD and IPF
An infection in progress
An evolutive cancer
Chemotherapy or radiation therapy in progress
Minors
Pregnant or lactating women
Majors under guardianship
People staying in a health or social facility
People in emergency
Non-beneficiaries of a social security scheme
Persons deprived of their liberty
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Audrey BENYAMINE, MD
Phone
+33 491386036
Email
audrey.benyamine@ap-hm.fr
First Name & Middle Initial & Last Name or Official Title & Degree
alexandra giuliani
Phone
0491382747
Email
drci@ap-hm.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
jean-olivier ARNAUD
Organizational Affiliation
Assistance Publique Hopitaux De Marseille
Official's Role
Study Director
Facility Information:
Facility Name
Assistance Publique Hopitaux de Marseille
City
Marseille
State/Province
BDR
ZIP/Postal Code
13354
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
ALEXANDRA GIULIANI, DRCI
Phone
0491382747
Email
drci@ap-hm.fr
First Name & Middle Initial & Last Name & Degree
audrey benyamine, md
12. IPD Sharing Statement
Learn more about this trial
Evaluation of the Serum Soluble Fractalkine as a Biomarker of Pulmonary Fibrosis in Systemic Sclerosis
We'll reach out to this number within 24 hrs